Trial Profile

Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms FRAIL-IMMUNE

19 Apr 2024 Status changed from recruiting to completed.
06 Jun 2023 Results (n=64) reporting safety and efficacy data at 18 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology
03 Oct 2022 Planned End Date changed from 1 Feb 2024 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com